European public procurement and grants data from official registers · Data as of 17 November 2026; updated daily.

Tenders

Pharmaceutical tenders in Germany

Pharmaceutical tenders in Germany: 3,945 listed on GranTender since 2024; 1,612 open now. The median awarded contract value is about €220,000 (818 contracts with a stated value). Buyers with the most tenders: DAK-Gesundheit (632), AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse (463) and AOK Bayern - Die Gesundheitskasse (426); suppliers with the most contract awards: BG Hexal 1 A Pharma GbR (1 A Pharma GmbH, H e x a l Aktiengesellschaft) (155), Zentiva Pharma GmbH (120) and Aliud Pharma GmbH (110). Sources: oeffentlichevergabe.de and TED. In 2025 the median contract value was €220,000; 18% of contracts drew a single bid (5.7 bids on average). Data as of 17 November 2026; updated daily.

Tenders
3,945
Open tenders
1,612
Awards
4,986
Awarded value awarded
€427,245,264
Awarded value contract
€13,301
Awarded value framework ceiling
€205,544,870
Median contract value awarded
≈ €220,000
Median contract value framework ceiling
≈ €230,000
Average bids per contract
6.5
Tenders in 2025
1,470 +16% on 2024

Median: contracts with a stated value, rounded. Average bids: contracts where the number of bids is published.

Value kinds: awarded — the value in the award decision; contract — the value of the signed or amended contract; paid — the amount actually paid; framework ceiling — the maximum of a framework agreement, given with every winner, not money spent. Different kinds are never added together.

Open tenders

TenderBuyerEstimated valueStatusPublished
Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-VerfahrenIKK classic—Open15 November 2026
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pazopanib (ATC-Code nach WHO: L01EX03)AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen—Open15 November 2026
Apothekendienstleistungen für KlinikenDRV Bund Einkaufsmanagement—Open13 November 2026
Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV95GWQ ServicePlus AG—Open13 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Atropin, ATC S01FA01AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Tiotropiumbromid, nur Inhalationslösung, ATC R03BB04AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Levothyroxin-Natrium, ATC H03AA01AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Calcipotriol und Betamethason, ohne Salben und Gele, ATC D05AX22AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Nintedanib, ATC L01EX09AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2027-01Deutsche Rentenversicherung Knappschaft-Bahn-See—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Fluorouracil, Kombinationen, ATC D11AF55AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Depemokimab, ATC R03DX12AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Follitropin delta, ATC G03GA10AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Brivaracetam, ATC N03AX23AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge Lipegfilgrastim, ATC L03AA14AOK Bayern - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Guselkumab, ATC L04AC16AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ranibizumab DFL (ATC-Code nach WHO: S01LA04)AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen—Open11 November 2026
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ranibizumab FER (ATC-Code nach WHO: S01LA04)AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen—Open11 November 2026
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aflibercept DFL (ATC-Code nach WHO: S01LA05; ausgenommen 114,3 mg/ml)AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen—Open11 November 2026
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aflibercept FER (ATC-Code nach WHO: S01LA05; ausgenommen 114,3 mg/ml)AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen—Open11 November 2026

Latest tenders

TenderBuyerEstimated valueStatusPublished
Lieferung von Keytrudaclinicpartner eG—Awarded15 November 2026
Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-VerfahrenIKK classic—Open15 November 2026
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pazopanib (ATC-Code nach WHO: L01EX03)AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen—Open15 November 2026
Lieferung von Enhertuclinicpartner eG—Awarded15 November 2026
Apothekendienstleistungen für KlinikenDRV Bund Einkaufsmanagement—Open13 November 2026
Abschluss nicht-exklusiver Rabattvereinbarung nach § 130a Abs. 8 bzw. § 130c Abs. 8 SGB V zu patentgeschützten Wirkstoffen-VV95GWQ ServicePlus AG—Open13 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Atropin, ATC S01FA01AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Tiotropiumbromid, nur Inhalationslösung, ATC R03BB04AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Levothyroxin-Natrium, ATC H03AA01AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Calcipotriol und Betamethason, ohne Salben und Gele, ATC D05AX22AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Nintedanib, ATC L01EX09AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2027-01Deutsche Rentenversicherung Knappschaft-Bahn-See—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Fluorouracil, Kombinationen, ATC D11AF55AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Depemokimab, ATC R03DX12AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Follitropin delta, ATC G03GA10AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Brivaracetam, ATC N03AX23AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge Lipegfilgrastim, ATC L03AA14AOK Bayern - Die Gesundheitskasse—Open12 November 2026
Open house Arzneimittelrabattverträge zum Wirkstoff Guselkumab, ATC L04AC16AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse—Open12 November 2026
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ranibizumab DFL (ATC-Code nach WHO: S01LA04)AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen—Open11 November 2026
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ranibizumab FER (ATC-Code nach WHO: S01LA04)AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen—Open11 November 2026

Competition and prices

In 2025, half of the contracts were worth between €120,000 and €270,000, with a median of €220,000 (361 contracts with a stated awarded value). Contracts drew 5.7 bids on average (median 4) and 18% drew a single bid — based on 1,144 contracts with a known number of bids. Compared with 2024, in 2025 the share of single-bid contracts rose from 12% to 18%. The usual procedures: open procedure (89%), negotiation without a call for competition (9%), negotiated procedure (1%) — of 3,881 tenders with a stated procedure.

The most contracts went to BG Hexal 1 A Pharma GbR (1 A Pharma GmbH, H e x a l Aktiengesellschaft) (155), Zentiva Pharma GmbH (120) and Aliud Pharma GmbH (110) — together 8% of all contracts.

YearContractsMedian valueMiddle half of valuesBids on averageSingle bid
20241,776€220,000€160,000 – €220,0006.212% (1,554)
20251,359€220,000€120,000 – €270,0005.718% (1,144)
2026 (so far)991€430,000€190,000 – €1 million4.815% (859)
All years4,987€220,000€140,000 – €430,0006.512% (4,348)

Values: contracts with a stated value in EUR, each value kind on its own (awarded or contract value), approximate (±3 %). Bids: contracts of procedures with competition whose number of bids the source publishes (1–100 bids); the sources publish it for some contracts only (TED ≈ 3 in 4, Spain all, Poland about half, Italy few), so each figure states its base and is shown from 20 contracts. A contract counts in the year of its award (else of its tender). Figures as of 13 November 2026, recomputed every week.

Where you have a chance

Since 1 November 2024, 17% of the 2,213 contracts with a known number of bids had a single bid; the median was 4 bids. The number of bids is known for 2,213 of the 2,306 contracts from procedures with competition.

Buyers who often get few offers

The buyers below usually received one or two offers per contract — an offer from you would stand out.

In the last 12 months, 55 companies won their first contract in our records here — 5% of the 1,117 contracts (our records start on 1 January 2024).

Contracts awarded since 1 November 2024 (the last 24 months). Bids as the source publishes them, 1 to 100 per contract, in procedures with competition only (a direct award has one offer by design). As of 13 November 2026.

Main CPV divisions

CPV codes of this topic

  • 33600000 Pharmaceutical products

A tender belongs here when its main CPV code starts with one of these codes; a tender without a usable CPV code (or with a general one) is matched by words of its title. A tender may belong to up to three topics.

Medicines and pharmaceuticals in neighbouring countries

Today, 286 tenders in the same niche are open in neighbouring countries.

Public tenders in the EU and the EEA are open to companies from every EU and EEA country on the same terms as local ones, and to companies from countries with a procurement agreement with the EU (such as Switzerland, the United Kingdom and Ukraine) for the contracts it covers. Open means the deadline has not passed (today's date). Neighbours: countries with a land border, a fixed link or a short sea crossing.

Expected soon3

ExpectedBuyerWhatWhy we expect itConfidence
now – Dec 2026
contract ends
Teilnehmende Gesundheitseinrichtungen der EKK plus GmbHMedicines and pharmaceuticals
Eisencarboxymaltose und Lacosamid
Typical value: ≈ €1,000
The current contract with Vivanta Generics s.r.o. ends on 31 December 2026; no new tender has been published yet.
Earlier tenders: 10/2025
high
now – Mar 2027
contract ends
Justizvollzugskrankenhaus Nordrhein-WestfalenMedicines and pharmaceuticals
Arzneimittel und apothekenpflichtige Medizinprodukte
The current contract with Katholische Kliniken im Märkischen Kreis gem. GmbH ends on 31 March 2027; no new tender has been published yet.
Earlier tenders: 09/2025
medium
Feb – Jul 2027
contract ends
BARMERMedicines and pharmaceuticals
Rabattvertrag nach §130a Abs.8 SGB V
The current contract with APONTIS PHARMA Deutschland GmbH & Co. KG ends on 31 July 2027; no new tender has been published yet.
Earlier tenders: 07/2025
high

Forecast from public data, not an announcement. Methodology.

Market reports

Medicines and pharmaceuticals by city

Medicines and pharmaceuticals in other countries

Medicines and pharmaceuticals across Europe

Topics in Health, medical equipment and medicines

Questions and answers

Which pharmaceutical tenders in Germany are open now?
1,612 of the 3,945 pharmaceutical tenders in Germany listed on GranTender are open for bids. For example: Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren; Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells z…; Apothekendienstleistungen für Kliniken.
Where can I find pharmaceutical tenders in Germany?
GranTender lists them in one place, from oeffentlichevergabe.de and TED, with their buyers, winners and contract values; 1,612 are open now. Search in one country at a time (the first 5 results) is free; search across all countries at once, full result lists, saved keywords with an e-mail once a week and exports come with a plan.
Who wins the most pharmaceutical tenders in Germany?
By number of contracts won: BG Hexal 1 A Pharma GbR (1 A Pharma GmbH, H e x a l Aktiengesellschaft) (155), Zentiva Pharma GmbH (120), Aliud Pharma GmbH (110).
Which buyers publish the most pharmaceutical tenders in Germany?
By number of tenders: DAK-Gesundheit (632), AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse (463), AOK Bayern - Die Gesundheitskasse (426).
Which CPV codes belong to “Medicines and pharmaceuticals”?
33600000 Pharmaceutical products; plus tenders without a usable CPV code whose title names the topic.
How many bids do pharmaceutical tenders in Germany receive on average?
In 2025, contracts drew 5.7 bids on average (median 4) and 18% drew a single bid — based on 1,144 contracts with a known number of bids.
How much are contracts for pharmaceutical tenders in Germany worth?
In 2025, half of the contracts were worth between €120,000 and €270,000, with a median of €220,000 (361 contracts with a stated awarded value). Compared with 2024, in 2025 the share of single-bid contracts rose from 12% to 18%.
Which procedures are used for pharmaceutical tenders in Germany?
The usual procedures: open procedure (89%), negotiation without a call for competition (9%), negotiated procedure (1%) — of 3,881 tenders with a stated procedure.
Which buyers get few offers in pharmaceutical tenders in Germany?
Since 1 November 2024, these buyers usually received one or two offers per contract: PBMG eG (median 2 bids over 281 contracts), Bundesamt für Infrastruktur, Umweltschutz und Dienstleistungen der Bundeswehr (median 1 bid over 30 contracts) and Teilnehmende Gesundheitseinrichtungen der EKK plus GmbH (median 2 bids over 8 contracts). Since 1 November 2024, 17% of the 2,213 contracts with a known number of bids had a single bid; the median was 4 bids.

CPV 2008 (Regulation (EC) No 213/2008), © European Union, Publications Office — via the eForms SDK, CC BY 4.0.